Clinical trials on Farxiga “have not reached a sufficient statistical level” to prevent mortality, the Swedish-British group said in a statement. Agerpres.
The tests were performed on a sample of 1,250 people, in collaboration with the American Institute of Cardiovascular Diseases Saint Luke’s Mid America. The full results of other tests will be made public in May.
This is a new failure of AstraZeneca, whose vaccine against COVID-19 is questioning the minds of doctors and patients.
Some countries have stopped using the vaccine, while others have set other age limits. For example, this vaccine is reserved for people over 30 in the United Kingdom, where it has been used en masse.
Serum distribution is also disrupted, with regular delays, as happened last week in the European Union.
In Romania, More than 57,000 doses of vaccine will arrive tomorrow, immunization with it continuing for all age groups.
AstraZeneca is also developing an antibody treatment against COVID-19, with the latest tests being conducted worldwide.
The US government has funded the development of this drug and the group plans to deliver up to 700,000 doses in the US this year.
If you like this article, we expect you to join the community of readers on our Facebook page, through a Like below: